VOR Heads Into Earnings With Shorts Under Pressure and Analysts Lifting Targets

VOR enters its August 18 earnings report in a genuinely charged position: short interest is massive at a third of the float, yet shorts have been quietly covering for a month while the stock climbs — and the Street just raised its target.

The most telling short-side dynamic is the direction of travel, not the size. Short interest is 33.7% of the free float — a structurally high reading for any stock — but the trend has moved against bears. From a peak near 7.85 million shares shorted at the start of July, positions have declined to 6.87 million, a drop of roughly 10% over the month. The week itself was mixed, with a 2.2% daily uptick on August 11 partly reversing a 4% weekly decline. The borrow market does not support a squeeze thesis at current levels: availability has loosened sharply, climbing to 151% from around 118% a week ago, meaning roughly 1.5 shares are available for every share already borrowed — well off the near-zero availability the lending market hit earlier in the year. Cost to borrow has also collapsed, down 45% over the past month to just 0.55%, the lowest level in the 30-day window. That combination — high but falling short interest, loose borrow, cheap to source — describes a short base that is trimming exposure rather than being squeezed out.

Options positioning has quietly shifted more cautious as the stock rallied. The put/call ratio moved to 0.39, above its 20-day average of 0.31 and running at roughly 1.7 standard deviations above that mean. It remains well below the 52-week high of 0.60, so the signal is more "elevated hedging" than outright fear — but the directional move over the past two weeks has been consistent, with the PCR rising from 0.27 to 0.39 as the stock gained 23% in a month. That suggests at least some participants are buying protection into the catalyst.

The Street picture is split but leaning upward. Six analysts hold buy ratings with a mean target of $40, implying around 70% potential return from the current $23.59 price. The most recent action came this morning: Wedbush lifted its target from $18 to $27 while holding its Neutral rating — a firm that has been consistently more cautious than the broader consensus. The bull case rests on telitacicept's clinical data across myasthenia gravis and Sjögren's disease, a cash runway into early 2029, and possible positive read-through if the FDA approves a competing mechanism in the same space. Bears point to small addressable markets in the initial indications, a Chinese partnership dependency via RemeGen, and zero revenue through 2026. The company ranks in the 98th percentile on EPS surprise — an impressive signal for a clinical-stage name — though the underlying multiples are all deeply negative, reflecting pre-revenue reality.

Institutional ownership adds a nuance worth noting. FMR (Fidelity) added nearly five million shares as recently as July, becoming the largest holder at 12% of shares. BlackRock added 2.7 million shares in the same period. Those are meaningful accumulation moves from index-adjacent but active managers. Meanwhile, RA Capital — a 10% owner with board representation — was a consistent seller in April, offloading shares across nine separate days at prices between $15.75 and $16.59. The stock now trades at $23.59. RA has since trimmed only minimally (a 213-share sale in July), suggesting the heavy distribution phase may have passed.

Prior earnings have produced wide swings: +10.5% and +11.5% in the one-day and five-day windows after June results, -3.4% / -3.6% after the May 18 event, and -8.5% / -5.6% after May 13. The pattern is binary rather than directional. With the ORTEX short score sitting at 71.5 — elevated but down from the 73-74 range seen in late July — and a next print due August 18, the setup to watch is whether that short score continues to ease alongside covering, or whether any clinical disappointment reignites the bear case into a float that is still one-third short.